EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Klinische Studie (Phase III)Open Access · CC BY-NC 4.0

Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysis

Franz J Legat iD, Shawn G Kwatra, Adam Reich, Serge Boulinguez, Athanasios Tsianakas, Maxwell Sauder iD, Sebastien Barbarot iD, Jacek C Szepietowski, Curdin Conrad iD, Andrew E Pink, Elke Weisshaar, Laurent Misery iD und 11 weitere

Journal of the European Academy of Dermatology and Venereology · 2025

DOI: 10.1111/jdv.70266 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2025. Verfasst von Franz J Legat und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Prurigo, Dermatologic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Galderma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Prurigo nodularis (PN) is a neuroimmune skin disease characterized by the presence of chronic itch (≥6 weeks) and multiple white‐pink papules, nodules and/or plaques.

Objectives

The OLYMPIA long‐term extension (OLYMPIA‐LTE) trial evaluates long‐term, over 184 weeks, safety and efficacy of nemolizumab in adults with moderate‐to‐severe PN.

Methods

Adults with moderate‐to‐severe PN, who completed phase 2b (NCT03181503) and phase 3 (OLYMPIA 1&2) lead‐in trials, were eligible for the ongoing OLYMPIA‐LTE trial. Patients receiving nemolizumab monotherapy (continuous‐nemolizumab) during lead‐in trials continued their regimen, while those on placebo (nemolizumab‐naïve) initiated nemolizumab monotherapy. The primary endpoint was long‐term safety. Efficacy assessments included the proportion of patients achieving a ≥4‐point improvement from baseline Peak Pruritus Numerical Rating Scale (PP‐NRS4), Sleep Disturbance Numerical Rating Scale (SD‐NRS4) and Dermatology Life Quality Index (DLQI4) scores, Investigator's Global Assessment (IGA) score 0/1 (clear/almost clear), and 75% healed pruriginous lesions (Prurigo Activity and Severity score item‐5b). Observed cases up to week 100, regardless of rescue medication, are presented, without imputation of missing data.

Results

At interim analysis data cut‐off (21 July 2024), 290/508 (57%) patients completed week 100 (median exposure: 839.5 days). Treatment‐emergent adverse events (TEAEs) occurred in 89% of patients (452/508; exposure time‐adjusted incidence rate: 197.5/100 patient‐years) and were mostly mild/moderate (26%/52%) in severity. TEAEs occurring in ≥5% of patients at any given year were COVID‐19 (28%), nasopharyngitis (20%), upper respiratory tract infection (13%), neurodermatitis (worsening of PN; 13%), back pain (9%), headache (9%), arthralgia (9%), cough (8%), hypertension (8%) and nummular eczema (8%). At week 100, among evaluable patients treated with nemolizumab, 92% achieved PP‐NRS4, 86% SD‐NRS4, 91% DLQI4, 74% IGA 0/1 and 84% observed healing of >75% of pruriginous lesions.

Conclusions

Long‐term treatment with nemolizumab was well tolerated and led to disease control with clinically meaningful improvements in itch intensity, pruriginous lesions and quality of life. Clinical Trial Registration No NCT04204616, RD.06.SPR.202699 and 2019‐004294‐13 (EudraCT Number).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedPrurigoDermatologic AgentsAdultFemaleHumansMaleMiddle AgedDouble-Blind MethodPruritusSeverity of Illness IndexTreatment Outcome

Stichwörter der Autor:innen

IL‐31chronic prurigoitchnemolizumabprurigo nodularispruritus

Substanzen

Antibodies, Monoclonal, HumanizednemolizumabDermatologic Agents

Autor:innen und Institutionen

  • Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria.
  • Department of Dermatology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Maryland Itch Center, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Department of Dermatology, University of Rzeszów, Rzeszów, Poland.
  • Department of Dermatology, Medical University of Toulouse, Toulouse, France.
  • Department of Dermatology, Fachklinik Bad Bentheim, Bad Bentheim, Germany.

ORCID-Profile: Franz J Legat, Maxwell Sauder, Sebastien Barbarot, Curdin Conrad, Laurent Misery, Martin Metz, Lone Skov, Christophe Piketty, Sonja Ständer

Förderung

  • Galderma

Zitieren

APA

Legat, F. J., Kwatra, S. G., Reich, A., Boulinguez, S., Tsianakas, A., Sauder, M., Barbarot, S., Szepietowski, J. C., Conrad, C., Pink, A. E., Weisshaar, E., Misery, L., Metz, M., Laquer, V. T., Sivamani, R. K., Yosipovitch, G., Thaçi, D., Skov, L., Chen, X., …, & Ständer, S. (2025). Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysis. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.70266

Vancouver

Legat FJ, Kwatra SG, Reich A, Boulinguez S, Tsianakas A, Sauder M, et al. Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysis. Journal of the European Academy of Dermatology and Venereology. 2025. doi:10.1111/jdv.70266

BibTeX
@article{Legat2025,
  author = {Legat, Franz J and Kwatra, Shawn G and Reich, Adam and Boulinguez, Serge and Tsianakas, Athanasios and Sauder, Maxwell and Barbarot, Sebastien and Szepietowski, Jacek C and Conrad, Curdin and Pink, Andrew E and Weisshaar, Elke and Misery, Laurent and Metz, Martin and Laquer, Vivian T and Sivamani, Raja K and Yosipovitch, Gil and Thaçi, Diamant and Skov, Lone and Chen, Xiaoxiao and Noda, Aliene and Jabbar-Lopez, Zarif K and Piketty, Christophe and Ständer, Sonja},
  title = {Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysis},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2025},
  doi = {10.1111/jdv.70266}
}
Kostenlos starten →